MedWatch

CHMP vouches for Ascendis Pharma's growth hormone for children

Ascendis Pharma is one step closer to launching its first drug in the EU, the growth hormone Skytrofa, as the EMA's expert committee, the CHMP, has given its positive recommendation for the treatment for children.

Photo: Kevin Grønnemann

Children and adolescents aged 3 to 18 years old with growth hormone deficiency (GHD) should be able receive treatment with Ascendis Pharma's growth hormone Skytrofa, says the European Medicines Agency's (EMA) Committee for Medicinal Products for Human Use (CHMP).

However, before the drug can marketed, the EU Commission must first ratify the proposal. Still, drugs that have received the CHMP's stamp of approval usually pass through the Commission within a few months, as its final decision is often more of a formality. In Ascendis Pharma's case, this is therefore expected to happen before the end of January.

Read the whole article

Get 14 days free access.

No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

Coloplast upgrades growth expectations following acquisition

Medtech firm Coloplast’s Q1 report for 2021/2022 brings a slight upward adjustment of the reported revenue growth outlook due to foreign exchange developments. Coloplast’s acquisition of Atos Medical is expected to contribute around 6 percent to organic growth.

Demant's surgical division loses president of 13 years

Oticon Medical, the implants division at hearing group Demant, is saying goodbye to President Jes Olsen, who is exiting his role in March after having spearheaded the business leg since 2008. Demant CEO Søren Nielsen is stepping in temporarily until a replacement is found.

Hearing aid market in US grew by 37 percent in 2021

Hearing aid manufacturers have had a good year following one of the worst in their recorded history, as sales in the US have gone up by 37 percent. The progress is mainly driven by the recovery of independent retailers, whereas public sales channel Veterans Affairs still lags behind.

Further reading

Related articles

Latest news

See all jobs